Substudy 06D is an open-label phase 1/2 umbrella platform trial evaluating the safety and efficacy of MK-2870 in combination with paclitaxel as second-line treatment in advanced or metastatic gastroesophageal adenocarcinoma. Eligible participants are adults with advanced or metastatic disease in the second-line setting. The objective of the study is to assess the safety and effectiveness of this combination regimen. The trial is conducted using an open-label platform design.
This phase 1/2 clinical trial is evaluating the investigational drug MK-2870 in combination with paclitaxel. The treatment is being studied in patients with advanced or metastatic cancer of the stomach or the junction between the esophagus and stomach. It is intended for patients whose disease has progressed after a first treatment. The goal of the study is to assess the safety and effectiveness of this combination as a second-line therapy. The trial is open-label, meaning both doctors and participants know which treatment is administered.
